ArticleChemical & biomedical imaging2025
pH-Responsive Liposomes for Targeted Detection of Pancreatic Adenocarcinoma Using MSOT.
Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterials for In Vivo Photoacoustic Sensing: Emerging Strategies and Future Outlook.ACS sensors · 2026Review
- Peptide-Based Probe Targeting Angiotensin Type‑1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography.Chemical & biomedical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) diagnosis and treatment are limited due to the insufficient availability of contrast agents that can detect tumors with high sensitivity and specificity. Nanocontrast agents can be actively targeted toward the highly acidic tumor microenvironment to facilitate the detection of tumor cells during intraoperative imaging using an advanced imaging modality: multispectral optoacoustic tomography (MSOT). We developed IR780 dye encapsulated liposomes (Lipo-780) as a nanocontrast agent and actively targeted them using the pH low insertion peptide (pHLIP) V7 (V7-lipo-780) toward the extremely acidic pH tumor microenvironment of pancreatic cancer. Tumor-specific uptake of liposomes were evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.